Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617.

ABSTRACT: The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617. Methods: 109 mCRPC patients treated with a median of 3 cycles of ¹⁷⁷Lu-PSMA-617 were included. Data were analyzed according to OS as well as PSA response patterns with regard to prior therapies, laboratory biomarkers and metastatic extent in univariate as well as multivariate Cox's proportional hazards models. PSA decline was assessed using the lowest PSA levels after the first cycle of therapy (initial PSA response) and during the entire observation period (best PSA response). Results: In total, 54 patients (49.5%) died during the observation period. First and second line c

SUBMITTER: Kessel K 

PROVIDER: S-EPMC6691377 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature